Amphastar Pharmaceuticals (NASDAQ:AMPH) Coverage Initiated at Wells Fargo & Company

Wells Fargo & Company initiated coverage on shares of Amphastar Pharmaceuticals (NASDAQ:AMPH - Free Report) in a report issued on Friday morning, MarketBeat reports. The firm issued an equal weight rating and a $55.00 price target on the stock.

A number of other analysts have also recently weighed in on the stock. Piper Sandler decreased their price target on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an "overweight" rating for the company in a research report on Thursday, August 8th. StockNews.com cut shares of Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, November 1st. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, Amphastar Pharmaceuticals presently has a consensus rating of "Hold" and a consensus price target of $60.33.

Amphastar Pharmaceuticals Price Performance

Shares of Amphastar Pharmaceuticals stock traded up $0.88 during trading on Friday, hitting $45.43. 269,426 shares of the company were exchanged, compared to its average volume of 397,386. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. Amphastar Pharmaceuticals has a fifty-two week low of $36.56 and a fifty-two week high of $65.92. The stock has a market capitalization of $2.18 billion, a price-to-earnings ratio of 14.82, a P/E/G ratio of 0.87 and a beta of 0.82. The firm has a 50 day moving average price of $48.31 and a 200 day moving average price of $44.42.

Insider Activity

In other news, EVP Rong Zhou sold 4,000 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $48.35, for a total value of $193,400.00. Following the completion of the transaction, the executive vice president now directly owns 118,388 shares in the company, valued at $5,724,059.80. This trade represents a 3.27 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Yakob Liawatidewi sold 5,214 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total transaction of $271,388.70. Following the completion of the transaction, the executive vice president now owns 74,938 shares of the company's stock, valued at $3,900,522.90. This trade represents a 6.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 31,533 shares of company stock worth $1,571,652. 27.10% of the stock is currently owned by corporate insiders.

Institutional Trading of Amphastar Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Aurora Investment Counsel lifted its position in shares of Amphastar Pharmaceuticals by 0.4% in the 3rd quarter. Aurora Investment Counsel now owns 54,698 shares of the company's stock valued at $2,654,000 after acquiring an additional 232 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Amphastar Pharmaceuticals by 70.0% in the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company's stock valued at $32,000 after acquiring an additional 273 shares in the last quarter. Crossmark Global Holdings Inc. lifted its position in shares of Amphastar Pharmaceuticals by 2.5% in the 2nd quarter. Crossmark Global Holdings Inc. now owns 11,300 shares of the company's stock valued at $452,000 after acquiring an additional 275 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Amphastar Pharmaceuticals by 20.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company's stock valued at $85,000 after acquiring an additional 301 shares in the last quarter. Finally, Blue Trust Inc. lifted its position in shares of Amphastar Pharmaceuticals by 23.9% in the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company's stock valued at $70,000 after acquiring an additional 309 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.